• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, September 29, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Examining the one-two punch of malaria drugs

Bioengineer by Bioengineer
May 5, 2021
in Chemistry
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Why the combination medicines both help and hurt each other

IMAGE

Credit: University of Houston

When a mosquito begins to nibble on you, it is not merely feeding on your blood, it is also injecting its saliva into your skin. If that saliva happens to be full of parasites carrying malaria or other diseases from its last victim, then most likely you will become infected, too.

The first-line treatment for malaria, caused by the P. Falciparum parasite, is artemisinin-based combination therapy, which provides a one-two punch. The drug artemisinin (derived from the Asian Artemisia annua or sweet wormwood) is combined with a quinoline-based compound. Artemisinin weakens the parasite by oxidizing it; the quinoline drug kills it.

“But the two drugs do not always cooperate, they can also be antagonistic. Our purpose is to study the interactions between artemisinin and the drugs with which they are combined to fight malaria,” said Peter Vekilov, Moores Professor of Chemical and Biomolecular Engineering at the University of Houston. Vekilov received $1.2 million from the National Institute of Health, in partnership with Johns Hopkins University, to study the interactions of the drugs. Working with Vekilov is Jeff Rimer, Abraham E. Dukler Professor of Chemical and Biomolecular Engineering at UH.

As their name indicates, parasites know how to survive and adapt. When they begin to eat away at hemoglobin, hematin is produced. The toxic hematin itself could kill the parasite, but the parasite makes quick work of the hematin.

“The parasite knows how to deal with hematin, by sequestering it as innocuous crystals called hemozoin which are no longer toxic,” said Vekilov. “There is a crucial gap in the understanding of interactions between drug pairs relating to how they inhibit hemozoin formation.”

Many anti-malarial drugs work by inhibiting crystallization, which leaves the hematin soluble to kill the parasites. In previous work, Vekilov and Rimer proved artemisinin can also kill parasites by blocking crystallization.

Still, as a high-level organism, the parasite has adapted quickly and developed a pump, which pumps the drugs out in a process Vekilov likens to warfare.

“When you want to defend yourself against bullets, you use armor, but if you want to protect yourself against grenades, you throw them back,” he said. “The parasite uses the second strategy.”

Malaria kills more than 400,000 people around the world every year, mostly young children. Although it was eliminated from the United States 70 years ago, it still infects 2,000 Americans each year. According to the Centers for Disease Control and Prevention, malaria cases in the United States rose to 2,161 in 2017, the highest number in 45 years.

Artemisinin was discovered in 1971 by a Chinese scientist who won the Nobel Prize in 2015 for discovering its antimalarial properties.

“Our long-range goal is to develop a platform which will allow us to produce new drugs before the parasites develop resistance to the old ones, because that is inevitable,” said Vekilov.

###

Media Contact
Laurie Fickman
[email protected]

Original Source

https://uh.edu/news-events/stories/2021/may-2021/05052021-vekilov-malaria-drugs-combination-antagonist.php

Tags: Biomedical/Environmental/Chemical EngineeringChemistry/Physics/Materials SciencesDeveloping CountriesDisease in the Developing WorldInfectious/Emerging DiseasesInternal MedicineMedicine/HealthneurobiologySocioeconomics
Share12Tweet8Share2ShareShareShare2

Related Posts

Breakthrough Computer Models Unlock Secrets of the Early Universe

September 29, 2025
Streamlined Forecasting of Aerodynamic Traits in Flexible Flapping Wings

Streamlined Forecasting of Aerodynamic Traits in Flexible Flapping Wings

September 29, 2025

Durable Lithium–Sulfur Batteries Enabled by CoWO4/WO2 Heterostructure Catalysts

September 29, 2025

Researchers Unveil Nanoscale Spin Maps in Chiral Perovskites

September 29, 2025
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    86 shares
    Share 34 Tweet 22
  • Physicists Develop Visible Time Crystal for the First Time

    73 shares
    Share 29 Tweet 18
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    57 shares
    Share 23 Tweet 14
  • Scientists Discover and Synthesize Active Compound in Magic Mushrooms Again

    56 shares
    Share 22 Tweet 14

About

BIOENGINEER.ORG

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Advancements in Laser Glass: A Strategic Approach to Designing Complex Materials

Food Addiction: Links to Health Issues and Well-Being

Omega-3 Fatty Acids Influence Mammary Gland Development and Lipogenesis through Gαs-Driven cAMP–EPAC Signaling Pathway

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 61 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.